OMDA Q2 2026: Steady Topline, Thin Margins — Waiting for GLP‑1 Proof

What happened

Omada reported Q2 2026 revenue of $89 million, up 31% year over year, slightly above Wall Street estimates, driven by 38% growth in enrolled members to 1.15 million. Gross margin held at 67% on a non-GAAP basis, but operating expenses grew 29% due to GLP‑1 launch investments and platform expansion, keeping adjusted EBITDA just below breakeven. The GLP‑1 prescribing program launched in late May, yet management disclosed only 2,300 enrolled prescribing members and deferred providing a full‑year contribution margin forecast. Related‑party revenue from Cigna affiliates contributed 42% of total revenue, down from 45% a year ago, but remains a concentrated risk. Internal controls remediation remains incomplete, with management now targeting full remediation by year‑end 2026.

Implication

The revenue beat and member growth provide comfort that the base narrative is intact, supporting a $13–$14 fair value. However, the absence of detailed GLP‑1 economics means the bull case remains unproven, and the stock will trade on initial utilization data. The elevated opex and delayed EBITDA inflection raise the risk that OMDA needs additional capital if cash burn persists beyond Q4 2026. Investors should watch for Q3 member retention and GLP‑1 attach rates as the next critical milestones; meanwhile, limit position size until profitability visibility improves. We maintain our POTENTIAL BUY rating but lower conviction to 3.0 and trim above $14.00, given the reduced probability of a sharp re‑rating before year‑end.

Thesis delta

The March 5 audited results validated FY2025 revenue at $258 million, meeting the trigger. However, Q2’s lack of GLP‑1 granularity and the EBITDA miss relative to our base case delay the profit pivot by one to two quarters, reducing the probability of near‑term upside. We adjust our 6‑month re‑assessment window to 9 months and lower conviction from 3.8 to 3.0.